La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Novonesis Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Ester Baiget

Amministratore delegato

€3.9m

Compenso totale

Percentuale dello stipendio del CEO	33.3%
Mandato del CEO	4.7yrs
Proprietà del CEO	n/a
Durata media del management	3.5yrs
Durata media del Consiglio di amministrazione	4.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29

Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Apr 12

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ester Baiget rispetto agli utili di Novonesis?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	€283m
Mar 31 2024	n/a	n/a	€332m
Dec 31 2023	€4m	€1m	€406m
Sep 30 2023	n/a	n/a	€430m
Jun 30 2023	n/a	n/a	€460m
Mar 31 2023	n/a	n/a	€487m
Dec 31 2022	€3m	€1m	€494m
Sep 30 2022	n/a	n/a	€460m
Jun 30 2022	n/a	n/a	€418m
Mar 31 2022	n/a	n/a	€416m
Dec 31 2021	€3m	€1m	€423m
Sep 30 2021	n/a	n/a	€427m
Jun 30 2021	n/a	n/a	€409m
Mar 31 2021	n/a	n/a	€389m
Dec 31 2020	€3m	€927k	€380m

Compensazione vs Mercato: La retribuzione totale di Ester ($USD 4.34M ) è circa la media per le aziende di dimensioni simili nel mercato Danish ($USD 3.69M ).

Compensazione vs guadagni: La retribuzione di Ester è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Ester Baiget (53 yo)

4.7yrs

Mandato

€3,903,958

Compensazione

Ms. Ester Baiget serves as Chief Executive Officer and President of Novozymes A/S since joining on February 1, 2020. She serves as Member of Supervisory Board at Akzo Nobel N.V. since 2022. She served as t...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Ester Baiget	President & CEO	4.7yrs	€3.90m	Nessun dato
Rainer Lehmann	Executive VP & CFO	less than a year	€858.60k	Nessun dato
Anders Lund	Chief Operating Officer	less than a year	€1.03m	Nessun dato
Claus Fuglsang	Chief Scientific Officer	4.1yrs	Nessun dato	Nessun dato
Tobias Bjorklund	Head of Investor Relations	no data	Nessun dato	Nessun dato
Tue Micheelsen	Vice President of Global Sales & Marketing	no data	Nessun dato	Nessun dato
Morten Rasmussen	Executive Vice President of People & Stakeholder Relations	3.5yrs	Nessun dato	Nessun dato
Tina Fano	Executive Vice President of Planetary Health Biosolutions	8.7yrs	€1.02m	Nessun dato
Amy Byrick	Executive Vice President of Human Health Biosolutions	3.5yrs	Nessun dato	Nessun dato
Henrik Nielsen	Executive Vice President of Strategy & Integration	less than a year	Nessun dato	Nessun dato
Jacob Paulsen	Executive Vice President of Food & Beverage Biosolutions	less than a year	Nessun dato	Nessun dato
Peter Rosholm	Chief Executive Officer of Albumedix	8.8yrs	Nessun dato	Nessun dato

3.5yrs

Durata media

50yo

Età media

Gestione esperta: Il team dirigenziale di NSIS B è considerato esperto (durata media dell'incarico 3.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jesper Brandgaard	Vice Chair of the Board	less than a year	Nessun dato	Nessun dato
Cornelis de Jong	Independent Chairman	4.7yrs	€239.07k	0.0011% DKK 2.3m
Kim Stratton	Independent Director	7.7yrs	€173.33k	Nessun dato
Kasim Kutay	Director	7.7yrs	€107.73k	0.00023% DKK 482.8k
Heine Dalsgaard	Director	4.7yrs	€143.55k	0.00065% DKK 1.4m
Lise Kaae	Director	less than a year	Nessun dato	Nessun dato
Anders Knudsen	Employee Representative Director	11.7yrs	€71.77k	Nessun dato
Sharon James	Independent Director	4.7yrs	€143.55k	Nessun dato
Anne Breum	Employee Representative Director	3.6yrs	€71.77k	0.00013% DKK 272.9k
Preben Nielsen	Employee Representative Director	3.6yrs	€107.73k	0.000090% DKK 188.9k
Jens Obro	Employee Representative Director	3.6yrs	€71.77k	0.00012% DKK 251.9k
Morten Otto Sommer	Independent Director	2.6yrs	€137.51k	0.00022% DKK 461.8k

4.1yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NSIS B sono considerati esperti (durata media dell'incarico 4 anni).

Novonesis Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Novozymes A/S Announces Board Appointments

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Independent Chairman recently bought kr.1.0m worth of stock

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Less than half of directors are independent

Recent updates

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Consensus EPS estimates increase by 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023